An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin® (GET)

Novo Nordisk

Status: Completed

Conditions: Adult Growth Hormone Deficiency; Growth Hormone Disorder

Treatments: Other: No treatment given; Drug: somatropin

Study type: Observational

Funder types: Industry

Identifiers

NCT00934063

GH-3709

Details and patient eligibility

About

This observational study is conducted in Europe. The aim of this observational study is to investigate the changes in a score (GET-score) which includes quality of life, body composition and cholesterol metabolism in patients on growth hormone treatment. The GET score stands for: Growth hormone deficiency and Efficacy of Treatment, and is a quantitative measurement of the efficacy of the treatment with growth hormone in adults.

Enrollment: 121 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Severe acquired growth hormone deficiency
• No treatment with somatropin in the last 24 months before study participation
• Written informed consent

Exclusion criteria

• Contraindications for the treatment with somatropin

Trial design

121 participants in 2 patient groups

A

Treatment:

Drug: somatropin

B

Treatment:

Other: No treatment given